Cargando…

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients

BACKGROUND: While many studies have previously focused on fingolimod's effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated. This study will elucidate what effects fingolimod treatment has on multiple sclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farrokhi, Mehrdad, Beni, Ali Amani, Etemadifar, Masoud, Rezaei, Ali, Rivard, Leah, Zadeh, Aryan Rafiee, Sedaghat, Nahid, Ghadimi, Milad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736130/ https://www.ncbi.nlm.nih.gov/pubmed/26900439 http://dx.doi.org/10.4103/2008-7802.172539

Ejemplares similares

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
por: Abdar, Morteza, et al.
Publicado: (2016)

Cardiovascular effects of fingolimod: A review article
por: Behjati, Mohaddeseh, et al.
Publicado: (2014)

Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial
por: Sayadishahraki, Masoud, et al.
Publicado: (2023)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Multiple sclerosis in sarcoidosis patients: Two case reports
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts
por: Hayward, Catherine P.M., et al.
Publicado: (2020)

COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

The Effect of Levothyroxine on Serum Levels of Interleukin 10 and Interferon-gamma in Rat Model of Multiple Sclerosis
por: Payghani, Cobra, et al.
Publicado: (2017)

Effects of whole body vibration on hormonal & functional indices in patients with multiple sclerosis
por: Ebrahimi, Ali, et al.
Publicado: (2015)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience
por: Huh, So-Young, et al.
Publicado: (2022)

Prevalence of Lhermitte's sign in multiple sclerosis versus neuromyelitis optica
por: Etemadifar, Masoud, et al.
Publicado: (2014)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

The relation between peptide hormones and sex hormone in patients with multiple sclerosis
por: Eftekhari, Elham, et al.
Publicado: (2013)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7v9h405bt9go70vqd61ro8vg98